WeChip Biotech: Microchip Biological's Sitagliptin and Metformin Extended-Release Tablets Receive Clinical Trial Approval Notification

K-LinePoet · 2026-03-20T19:49:06+00:00

Microchip Biotech announced that the company and its wholly-owned subsidiary, Chengdu Microchip Pharmaceuticals Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company's product, saxagliptin metformin extended-release tablets, to conduct clinical trials. Saxagliptin metformin extended-release tablets is a fixed-dose combination extended-release formulation of saxagliptin and metformin independently developed by the company, suitable for adult patients with type 2 diabetes mellitus who are appropriate for treatment with both saxagliptin and metformin, to improve blood glucose control in such patients.

K-LinePoet

2026-03-20 19:49:06

Microchip Biotech Announcement: The company and its wholly-owned subsidiary, Chengdu Microchip Pharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving the company’s product, Sitagliptin Sodium and Metformin Extended-Release Tablets, to conduct clinical trials. Sitagliptin Sodium and Metformin Extended-Release Tablets are a fixed-dose combination sustained-release formulation independently developed by the company, suitable for adult patients with type 2 diabetes who are appropriate for treatment with sitagliptin sodium and metformin, to improve blood sugar control in such patients.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes